OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: Duke University

13 Projects | 8 Researchers | $2,987,888 Invested

2017

Duke University

Miles Berger, MD, PhD

A Phase II Study of the ApoE mimetic peptide drug CN-105 to reduce Postoperative Delirium and Cognitive Dysfunction after Non-Cardiac Surgery in Older Adults and to Block their Underlying Mechanisms

  • Funding Amount: $1,631,197
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: zzAPOE
  • Status: Active

2014

Duke University

Carol Colton, PhD

Slowing arginine utilization by inhibiting arginase and ornithine decarboxylase with DFMO

  • Funding Amount: $155,051
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Neuroinflammation
  • Status: Closed

2013

Duke University

Donald Lo, PhD

Brain slice screen for microRNA-targeted drug lead candidates for tau-associated FTD

  • Funding Amount: $149,603
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2012

Duke University

Li Huang, PhD

Proteasome activator as drug candidates in Alzheimer's disease

  • Funding Amount: $100,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2011

Duke University

Li Huang, PhD

Proteasome Activator as Drug Candidates in Alzheimer's Disease

  • Funding Amount: $130,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2011

Duke University

Donald Lo, PhD

Optimization and Pre-Clinical Proof-of Concept of a New Drug Lead Candidate Series for Alzheimer's Disease

  • Funding Amount: $150,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2010

Duke University

Allen Roses, MD

Fine-mapping and characterization of genetic biomarkers that facilitate the acceleration of drug discovery for frontotemporal dementias

  • Funding Amount: $125,000
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Status: Closed

2009

Duke University

Rima Kaddurah-Daouk, PhD

Metabolomic Signatures of Preclinical and Early Alzheimer's Disease: Discovery of Novel Biomarkers for Drug and Disease Monitoring

  • Funding Amount: $120,000
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Status: Closed

2008

Duke University

Daniel Laskowitz, PhD

A novel apoE-derived therapeutic reduces AD pathology

  • Funding Amount: $85,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2006

Duke University

Daniel Laskowitz, PhD

A novel apoE-derived therapeutic reduces AD pathology

  • Funding Amount: $93,449
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed
View More